Mafoprazine(Mafoprazine) - 药物靶点：D2 receptor_在研适应症：精神障碍_专利_临床

概要

基本信息

药物类型

小分子化药

别名-

靶点

D2 receptor

作用机制

D2 receptor拮抗剂(多巴胺D2受体拮抗剂)

治疗领域

其他疾病

在研适应症

精神障碍

非在研适应症-

原研机构

Tanabe Seiyaku Co., Ltd. /Pet Medicine Operations/

在研机构

Tanabe Seiyaku Co., Ltd. /Pet Medicine Operations/

非在研机构-

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

结构

分子式C22H28FN3O3

InChIKeyPHOCQBYGUQPMIB-UHFFFAOYSA-N

CAS号80428-29-1

关联

100 项与 Mafoprazine 相关的临床结果

登录后查看更多信息

100 项与 Mafoprazine 相关的转化医学

登录后查看更多信息

100 项与 Mafoprazine 相关的专利（医药）

登录后查看更多信息

1

项与 Mafoprazine 相关的文献（医药）

1989-01-01·The Japanese Journal of Pharmacology

Effects of mafoprazine, a phenylpiperazine derivative, on the central dopaminergic system.

Article

作者: Kiyoshi Kinoshita ; Hiroyuki Nakagawa ; Ryuichi Ishida ; Kayoko Maeda ; Michio Yamamura

The effects of mafoprazine, a new phenylpiperazine derivative, on the central dopaminergic system were studied. Mafoprazine, like chlorpromazine and haloperidol, reduced the apomorphine-induced cage-climbing behavior in mice, emesis in dogs and stereotyped behavior in monkeys; methamphetamine-induced hyperlocomotion and group toxicity in mice; and agitation in rats. Mafoprazine inhibited the unilateral circling behavior induced by methamphetamine and apomorphine in rats with 6-hydroxydopamine-induced lesions in the unilateral nigrostriatal neuronal tract. The potency of mafoprazine in these experiments was almost equal to that of chlorpromazine and about one-tenth that of haloperidol. The cataleptogenic activity of mafoprazine was lower than those of chlorpromazine and haloperidol. Mafoprazine potentiated clonidine-induced hypothermia. These results suggest that mafoprazine has a relatively selective postsynaptic dopamine D2-receptor blocking action in the nucleus accumbens compared with chlorpromazine and haloperidol and suggest that mafoprazine also has alpha 2-adrenoceptor-stimulating actions.

100 项与 Mafoprazine 相关的药物交易

登录后查看更多信息